Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arch Therapeutics ( (ARTH) ) just unveiled an announcement.
On February 3, 2025, Arch Therapeutics, a company in the medical technology sector, experienced a significant leadership change. Michael S. Abrams resigned from his roles as Chief Financial Officer and Treasurer, with immediate effect, and waived any claims to financial obligations under his contract. Concurrently, Terrence W. Norchi, the current CEO, Chairman, President, and Secretary, has been appointed to assume the additional responsibilities of Principal Accounting Officer and Treasurer.
More about Arch Therapeutics
YTD Price Performance: 20.59%
Average Trading Volume: 8,164
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $913.5K
For a thorough assessment of ARTH stock, go to TipRanks’ Stock Analysis page.